Bilal Piperdi

16.8k total citations · 5 hit papers
119 papers, 5.0k citations indexed

About

Bilal Piperdi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Bilal Piperdi has authored 119 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 82 papers in Pulmonary and Respiratory Medicine and 23 papers in Surgery. Recurrent topics in Bilal Piperdi's work include Lung Cancer Treatments and Mutations (64 papers), Cancer Immunotherapy and Biomarkers (59 papers) and Colorectal Cancer Treatments and Studies (30 papers). Bilal Piperdi is often cited by papers focused on Lung Cancer Treatments and Mutations (64 papers), Cancer Immunotherapy and Biomarkers (59 papers) and Colorectal Cancer Treatments and Studies (30 papers). Bilal Piperdi collaborates with scholars based in United States, Spain and Australia. Bilal Piperdi's co-authors include Román Pérez-Soler, Sanatan Saraf, Anne Morosky, Dong‐Wan Kim, Patrick A. Ott, Sandrine Hiret, Janice M. Mehnert, Mario E. Lacouture, Ahmad Daniyal Siddiqui and Armando Santoro and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Bilal Piperdi

115 papers receiving 4.9k citations

Hit Papers

A Randomized, Placebo-Controlled Trial of Pembrolizumab P... 2017 2026 2020 2023 2020 2017 2017 2021 2021 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
    2020 409 citations Luis Paz‐Ares, David Vicente et al. Journal of Thoracic Oncology profile →
  2. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
    2017 363 citations Sanatan Saraf, Bilal Piperdi et al. Journal of Clinical Oncology profile →
  3. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    2017 325 citations Sanatan Saraf, Bilal Piperdi et al. profile →
  4. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
    2021 201 citations Roy S. Herbst, Byoung Chul Cho et al. Journal of Thoracic Oncology profile →
  5. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
    2021 165 citations Michael Boyer, Mehmet Alı Nahıt Şendur et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bilal Piperdi United States 35 3.9k 2.8k 821 529 518 119 5.0k
Aleksandra Szczęsna Poland 23 4.4k 1.1× 4.2k 1.5× 1.2k 1.4× 463 0.9× 665 1.3× 73 5.8k
Francesco Orlandi United States 17 4.9k 1.3× 3.2k 1.2× 806 1.0× 887 1.7× 565 1.1× 39 5.6k
Shunichi Sugawara Japan 36 4.2k 1.1× 3.5k 1.3× 1.1k 1.3× 507 1.0× 548 1.1× 209 5.4k
Hidetoshi Hayashi Japan 36 3.7k 1.0× 2.8k 1.0× 1.4k 1.7× 270 0.5× 705 1.4× 248 5.2k
Piotr Serwatowski Germany 15 4.0k 1.0× 3.5k 1.3× 1.0k 1.3× 415 0.8× 626 1.2× 28 5.3k
Patrick M. Forde United States 40 4.0k 1.0× 2.7k 1.0× 934 1.1× 301 0.6× 645 1.2× 186 5.7k
Nick Thatcher United Kingdom 34 4.0k 1.0× 3.9k 1.4× 1.5k 1.8× 434 0.8× 810 1.6× 117 5.7k
Biagio Ricciuti United States 33 2.6k 0.7× 1.7k 0.6× 1.1k 1.3× 322 0.6× 774 1.5× 161 3.8k
P. Murawa Poland 16 3.0k 0.8× 1.2k 0.4× 890 1.1× 605 1.1× 1.1k 2.1× 47 4.1k
Stefan Boeck Germany 36 3.4k 0.9× 1.2k 0.4× 805 1.0× 852 1.6× 1.2k 2.2× 145 4.3k

Countries citing papers authored by Bilal Piperdi

Since Specialization
Citations

This map shows the geographic impact of Bilal Piperdi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bilal Piperdi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bilal Piperdi more than expected).

Fields of papers citing papers by Bilal Piperdi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bilal Piperdi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bilal Piperdi. The network helps show where Bilal Piperdi may publish in the future.

Co-authorship network of co-authors of Bilal Piperdi

This figure shows the co-authorship network connecting the top 25 collaborators of Bilal Piperdi. A scholar is included among the top collaborators of Bilal Piperdi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bilal Piperdi. Bilal Piperdi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Boyer, Michael, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, et al.. (2021). Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology. 39(21). 2327–2338. 165 indexed citations breakdown →
3.
Awad, Mark M., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2021). OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology. 16(1). S8–S8. 1 indexed citations
4.
5.
Chandwani, Sheenu, et al.. (2019). P2.16-41 Pembrolizumab for Previously Treated, PD-L1–Expressing Advanced NSCLC: Real-World Time on Treatment and Overall Survival. Journal of Thoracic Oncology. 14(10). S882–S882. 1 indexed citations
6.
Halmos, Balázs, Alexander Luft, Margarita Majem, et al.. (2018). MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S391–S391. 4 indexed citations
7.
Mazières, Julien, Dariusz M. Kowalski, Alexander Luft, et al.. (2018). Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407. Annals of Oncology. 29. viii748–viii749. 2 indexed citations
8.
Kato, Terufumi, Ying Cheng, Kyoung Bun Lee, et al.. (2018). Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup. Annals of Oncology. 29. ix151–ix151. 4 indexed citations
9.
Dietel, Manfred, Н. А. Савелов, Patrick Micke, et al.. (2018). 130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study. Journal of Thoracic Oncology. 13(4). S74–S75. 13 indexed citations
10.
Zhou, C.Z., Christian Caglevic, Jianying Zhou, et al.. (2017). KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (NSCLC). Annals of Oncology. 28. x143–x143. 3 indexed citations
11.
Patel, Sandip Pravin, Nathan A. Pennell, Suchita Pakkala, et al.. (2016). Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi449–vi449. 2 indexed citations
12.
Li, Tianhong, Bilal Piperdi, William Walsh, et al.. (2016). Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer. Clinical Lung Cancer. 18(1). 60–67. 6 indexed citations
13.
Lee, J.-S., et al.. (2015). 461P Patients (Pts) with advanced NSCLC from Korea treated with pembrolizumab (Pembro) in KEYNOTE-001. Annals of Oncology. 26. ix125–ix125.
14.
Ahn, Myung‐Ju, Leena Gandhi, Omid Hamid, et al.. (2015). 459P Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001. Annals of Oncology. 26. ix125–ix125. 15 indexed citations
15.
Zou, Yiyu, Yi‐He Ling, Juan Sironi, et al.. (2013). The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib. Journal of Thoracic Oncology. 8(6). 693–702. 104 indexed citations
16.
Piperdi, Bilal, et al.. (2011). Preemptive Management of Dermatologic Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors. Clinical journal of oncology nursing. 15(5). 501–508. 11 indexed citations
17.
McDade, Theodore P., Bilal Piperdi, Sidney P. Kadish, et al.. (2010). A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database. HPB. 12(3). 204–210. 29 indexed citations
18.
McDade, Theodore P., Joshua S. Hill, Jessica P. Simons, et al.. (2010). A national propensity‐adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma. Cancer. 116(13). 3257–3266. 18 indexed citations
19.
20.
Piperdi, Bilal, Yi‐He Ling, & Román Pérez-Soler. (2007). Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell Lines. Journal of Thoracic Oncology. 2(8). 715–721. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aleksandra Szczęsna Breakdown of academic impact, for papers by Francesco Orlandi Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Hidetoshi Hayashi Breakdown of academic impact, for papers by Piotr Serwatowski Breakdown of academic impact, for papers by Patrick M. Forde Breakdown of academic impact, for papers by Nick Thatcher Breakdown of academic impact, for papers by Biagio Ricciuti Breakdown of academic impact, for papers by P. Murawa Breakdown of academic impact, for papers by Stefan Boeck
Rankless by CCL
2026